Discovery and pre-clinical characterization of a selective PI3Kδ inhibitor, LL-00071210 in rheumatoid arthritis

PI3Kδ plays a critical role in adaptive immune cell activation and function. Suppression of PI3Kδ has been shown to counter excessive triggering of immune responses which has led to delineating the role of this isoform in the pathophysiology of autoimmune disorders. In the current study, we have des...

Full description

Saved in:
Bibliographic Details
Published in:European journal of pharmacology 2022-07, Vol.927, p.175054-175054, Article 175054
Main Authors: Kanoje, Vijay, Pandey, Dilip, Wagh, Akshaya, Patra, Sukanya, Kumar Marisetti, Ajit, Reddy, Madhusudhan, Samant, Charudatt, Mahajan, Nilesh, Gholve, Milind, Sabde, Sudeep, Trivedi, Sneha, Bhankhede, Trupti, Patil, Vinod, Nigade, Prashant, Modi, Dipak, Mehta, Maneesh, Ahirrao, Prajakta, Tota, Swathi, Nanda, Bidyut, Pawar, Shashikant, Polawar, Anuradha, Tamane, Kaustubh, Kuldharan, Sandip, Vishwase, Gururaj, Jana, Nirmal, Mahangare, Sachin J., Vidhate, Prashant, Lagad, Dipak, Gundu, Jayasagar, Phukan, Samiron, Shukla, Manojkumar, Narasimham, Lakshmi, Nemmani, Kumar V.S., Bhonde, Mandar, Sharma, Sharad, Kamboj, Rajender K., Palle, Venkata P.
Format: Article
Language:English
Subjects:
Autoimmune diseases
Phosphoinositol 3-kinases
PI3K's
PI3Kδ
Rheumatoid arthritis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:PI3Kδ plays a critical role in adaptive immune cell activation and function. Suppression of PI3Kδ has been shown to counter excessive triggering of immune responses which has led to delineating the role of this isoform in the pathophysiology of autoimmune disorders. In the current study, we have described preclinical characterization of PI3Kδ specific inhibitor LL-00071210 in various rheumatoid arthritis models. LL-00071210 displayed excellent in vitro potency in biochemical and cellular assay against PI3Kδ with IC50 values of 24.6 nM and 9.4 nM, respectively. LL-00071210 showed higher selectivity over PI3Kγ and PI3Kβ as compared to available PI3K inhibitors. LL-00071210 had good stability in liver microsomes and plasma across species and showed low clearance, low-to-moderate Vss, with bioavailability of >50% in preclinical species. LL-00071210 demonstrated excellent in vivo efficacy in adjuvant-induced and collagen-induced arthritis models. Co-administration of LL-00071210 and methotrexate at subtherapeutic dose regimen in collagen induced arthritis model led to additive effects, indicating the combination potential of LL-00071210 along with available disease modifying anti-rheumatic drugs (DMARD). In conclusion, we have described a specific PI3Kδ inhibitor with ∼100-fold selectivity over other PI3K isoforms. LL-00071210 has good drug-like properties and thus warrants testing in the clinic for the treatment of autoimmune diseases.
ISSN:0014-2999
1879-0712
DOI:10.1016/j.ejphar.2022.175054